Propranolol vs Tadalafil
FDA Approved vs FDA Approved
compatible Researched · 90% Propranolol and tadalafil can be used concurrently. Beta blockers may theoretically contribute to erectile difficulties, but low-dose propranolol used for heart rate management during AAS cycles rarely causes significant erectile dysfunction. Tadalafil's PDE5 inhibition operates independently of beta-adrenergic pathways. Monitor blood pressure, as both agents lower BP through different mechanisms.
Molecular Data
Propranolol Tadalafil
Weight 259.34 Da 389.40 Da
Half-life ~4-5 hours ~17.5 hours
Type Aryloxypropanolamine derivative (C16H21NO2) Small molecule phosphodiesterase type 5 (PDE5) inhibitor
Key Benefits
Propranolol
01 Rapid reduction of elevated heart rate within 30-60 minutes of oral dosing
02 Effective against tachycardia from both trenbolone and clenbuterol through non-selective beta blockade
03 Well-established anxiolytic effect for performance anxiety without cognitive impairment or sedation
04 Short half-life allows flexible as-needed dosing without prolonged hemodynamic effects
05 Extensive clinical safety data spanning over 50 years of use
06 Inexpensive and widely available as a generic medication
07 Does not cause dependence or withdrawal symptoms typical of benzodiazepines
08 Effective for controlling physical anxiety symptoms (tremor, palpitations, sweating)
Tadalafil
01 Long-acting duration with a 36-hour therapeutic window
02 Daily low-dose option (2.5-5mg) eliminates timing constraints
03 FDA-approved for both ED and BPH/LUTS
04 Minimal food interaction compared to other PDE5 inhibitors
05 Improved endothelial function and blood flow
06 Lower incidence of visual side effects vs. sildenafil
07 Potential benefits for exercise performance via enhanced blood flow
08 Well-established long-term safety profile
Side Effects
Propranolol
Fatigue and reduced exercise tolerance, particularly during the first week of use
Cold extremities (hands and feet) due to beta-2 blockade of peripheral vasodilation
Bradycardia (heart rate below 60 bpm), usually dose-dependent and asymptomatic
Dizziness or lightheadedness, especially when standing quickly
Gastrointestinal discomfort (nausea, diarrhea, constipation)
Tadalafil
Headache (11-15% incidence, most common side effect)
Dyspepsia / indigestion (4-13%)
Back pain (3-9%, relatively unique to tadalafil among PDE5 inhibitors)
Myalgia / muscle aches (1-7%, thought to be related to PDE11 inhibition)
Nasal congestion / rhinitis (3-5%)
Flushing (1-4%)
Limb pain (1-3%)
Dizziness (1-2%)
Contraindications
Asthma or severe reactive airway disease (non-selective beta blockade can trigger life-threatening bronchospasm)
Decompensated heart failure or cardiogenic shock
Sinus bradycardia (resting HR below 50 bpm) or second/third-degree heart block
Severe peripheral arterial disease or Raynaud's syndrome
Pheochromocytoma without prior alpha blockade (risk of hypertensive crisis from unopposed alpha stimulation)
Concurrent use of any organic nitrate medication (absolute contraindication)
Concurrent use of guanylate cyclase stimulators (e.g., riociguat)
Known hypersensitivity to tadalafil or any tablet excipient
Severe hepatic impairment (Child-Pugh Class C)
Recent stroke or myocardial infarction (within 90 days)
Unstable angina or angina during sexual intercourse
Uncontrolled hypertension (>170/100 mmHg) or hypotension (<90/50 mmHg)
NYHA Class IV heart failure
Hereditary degenerative retinal disorders (including retinitis pigmentosa)
History of NAION (relative contraindication -- increased recurrence risk)
Research Evidence
Propranolol Tadalafil
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2023 —
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.